Spots Global Cancer Trial Database for Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
Official Title:
Study ID: NCT03008343
Conditions
Study Description
Brief Summary: The aim of this study is the safety and efficacy of irreversible electroporation (IRE) plus natural killer (NK) immunotherapy to recurrent liver cancer.
Detailed Description: By enrolling patients with recurrent liver cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using IRE and NK cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Eligibility
Minimum Age: 30 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fuda cancer institute of Fuda cancer hospital, Guangzhou, Guangdong, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
